Infectious Disease Therapeutics Market by Therapeutic Type (Antiviral Drugs, Antibiotics and Antifungal Agents, Antibacterial Drugs, Others); Pathogen Type (Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections); Route of Administration (Oral, Injectable, Topical); End-Use Industry (Hospitals, Ambulatory Surgical Centers, Others) and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Infectious Disease Therapeutics Market was valued at USD 87.1 Billion in 2024-e and will surpass USD 134.3 Billion by 2030; growing at a CAGR of 7.5% during 2025 - 2030.

The Infectious Disease Therapeutics market is a crucial segment of the global healthcare industry, driven by the growing prevalence of infectious diseases, the emergence of new pathogens, and the increasing incidence of antimicrobial resistance (AMR). Infectious diseases, whether bacterial, viral, fungal, or parasitic, continue to pose significant public health challenges worldwide. The demand for effective therapeutics is on the rise, particularly in light of the ongoing need for treatments for emerging infectious diseases, such as COVID-19, and the growing burden of chronic infections. The market encompasses a wide range of therapeutic options, including antiviral drugs, antibiotics, antifungal agents, and other treatments, designed to target specific pathogens and alleviate the symptoms of these diseases.

With significant advancements in medical research, pharmaceutical companies are developing innovative treatments to address both common and rare infectious diseases. The market is evolving with the introduction of new drug classes, such as novel antiviral agents and next-generation antibiotics, aimed at combating resistant strains of bacteria and viruses. Additionally, the growing focus on personalized medicine, which tailors treatments based on individual genetic profiles, is shaping the future of the infectious disease therapeutics market. As the global healthcare landscape continues to address the challenges posed by infectious diseases, the demand for effective, targeted therapies will remain a central focus.

Antiviral Drugs Are Largest Segment Owing to High Demand for Treatment of Viral Infections

Antiviral drugs represent the largest segment of the infectious disease therapeutics market due to the growing burden of viral infections worldwide. Viral diseases, including influenza, HIV/AIDS, hepatitis, and more recently COVID-19, continue to have a significant impact on public health. Antiviral drugs play a pivotal role in controlling the spread and progression of viral infections, reducing morbidity and mortality, and improving patient outcomes. The development of antiviral treatments has accelerated, particularly in response to the COVID-19 pandemic, with a surge in demand for effective antiviral therapies.

The antiviral drug segment includes treatments targeting various viruses, such as direct-acting antivirals (DAAs) for hepatitis C, antiretrovirals for HIV/AIDS, and antivirals for influenza and COVID-19. These drugs work by inhibiting viral replication, preventing the spread of the infection, and improving the body’s immune response. With the ongoing threat of new and emerging viral pathogens, the demand for antiviral drugs is expected to remain high, making it the largest therapeutic type in the market. Pharmaceutical companies continue to invest heavily in antiviral drug development, particularly as new antiviral therapies offer greater efficacy and fewer side effects compared to older treatments.

Antibiotics and Antifungal Agents Are Fastest Growing Therapeutic Type Due to Increasing Incidence of Resistant Infections

Antibiotics and antifungal agents are the fastest-growing therapeutic type within the infectious disease therapeutics market, driven by the increasing incidence of antimicrobial resistance (AMR). Antibiotics remain the primary treatment for bacterial infections, but the rise of antibiotic-resistant bacteria poses a significant challenge to healthcare systems globally. Antifungal agents are increasingly important in treating fungal infections, particularly in immunocompromised patients. The emergence of resistant strains of both bacteria and fungi has led to an urgent need for new and more effective antibiotics and antifungal drugs.

Pharmaceutical companies are focusing on developing novel antibiotics and antifungal agents that can target resistant strains, including multi-drug resistant bacteria and difficult-to-treat fungal infections. These new drugs aim to address the growing concerns surrounding AMR and provide healthcare professionals with more treatment options. The growing prevalence of hospital-acquired infections (HAIs), particularly in intensive care units, further fuels the demand for antibiotics and antifungal agents. As the number of resistant infections continues to rise, this segment is expected to experience rapid growth in the coming years, driven by both the need for innovative treatments and increasing investments in the development of new antibiotics and antifungal therapies.

Oral Administration Is Largest Route of Administration Owing to Ease of Use

The oral route of administration is the largest segment in the infectious disease therapeutics market due to its ease of use, convenience, and patient compliance. Oral drugs are typically preferred by patients because they can be taken at home without the need for medical supervision, unlike injectable drugs. Oral antibiotics, antivirals, and antifungal agents are widely used to treat a variety of infectious diseases, including respiratory infections, gastrointestinal infections, and skin infections. This makes the oral route the most popular and widely used administration method in the treatment of infectious diseases.

The ease of administering oral medications has led to their widespread adoption, particularly in outpatient settings where patients require long-term treatment for chronic infections. Oral medications also allow for better patient adherence to treatment regimens, which is essential for ensuring the success of the therapy and preventing the development of resistant infections. With ongoing advancements in oral drug formulations, such as extended-release and controlled-release formulations, the oral administration segment is expected to continue to dominate the market, offering both patients and healthcare providers a convenient and effective method of treatment.

Hospitals Are Largest End-Use Industry Due to High Treatment Volume

Hospitals are the largest end-use industry in the infectious disease therapeutics market, owing to their central role in the diagnosis and treatment of infectious diseases. Hospitals are the primary healthcare settings where patients with severe or complicated infections receive treatment, particularly those requiring hospitalization for intravenous (IV) antibiotic administration or intensive care. In hospitals, a wide range of infectious diseases are treated, from common infections to complex cases, including multi-drug resistant infections and opportunistic infections in immunocompromised patients.

Hospitals are equipped with advanced diagnostic tools and skilled healthcare professionals capable of diagnosing and managing complex infectious diseases. The demand for infectious disease therapeutics in hospitals is driven by the need for effective treatments to manage hospital-acquired infections (HAIs) and the increasing prevalence of infectious diseases globally. The growing burden of chronic infections, such as HIV/AIDS, tuberculosis, and hepatitis, further increases the demand for therapeutics in hospital settings. As the primary providers of acute care, hospitals will continue to be the largest end-use industry for infectious disease therapeutics.

North America Is Largest Region Due to Advanced Healthcare Systems

North America is the largest region in the infectious disease therapeutics market, driven by its advanced healthcare infrastructure, high healthcare expenditure, and robust research and development activities. The United States and Canada have well-established healthcare systems and are home to some of the largest pharmaceutical companies globally, which continue to invest in the development of innovative therapeutics. Additionally, North America is a hub for the development and approval of new drugs, with stringent regulatory processes that ensure the safety and efficacy of therapeutics.

The region’s dominance is also supported by its strong healthcare reimbursement systems, which facilitate access to cutting-edge therapies for patients. Furthermore, the growing incidence of infectious diseases, particularly viral infections such as influenza, HIV, and COVID-19, has driven the demand for effective therapeutics. North America’s strong healthcare market, combined with its focus on research and innovation, will continue to solidify its position as the largest region in the infectious disease therapeutics market.

Leading Companies and Competitive Landscape

The infectious disease therapeutics market is highly competitive, with several global pharmaceutical companies leading the way in the development of innovative treatments for infectious diseases. Key players in the market include Pfizer, Merck & Co., Johnson & Johnson, Gilead Sciences, Novartis, AbbVie, and Sanofi, among others. These companies are focused on expanding their portfolios to include new antiviral, antibiotic, and antifungal therapies, particularly those targeting drug-resistant infections.

The competitive landscape is characterized by significant investment in research and development, as companies race to develop new treatments for emerging and resistant infections. Additionally, collaborations, acquisitions, and partnerships are common as companies seek to enhance their capabilities and expand their market share. The market is also seeing a growing trend toward personalized medicine, where treatments are tailored to individual patient needs. As the global burden of infectious diseases continues to rise, these leading companies will play a critical role in shaping the future of the infectious disease therapeutics market.

Recent Developments:

• Merck & Co., Inc. launched a new antiviral drug for the treatment of COVID-19, reducing hospitalization rates by up to 50%.
• Pfizer Inc. received FDA approval for its new broad-spectrum antibiotic to treat bacterial infections, addressing rising concerns of antimicrobial resistance.
• Gilead Sciences expanded its portfolio with a novel drug for treating multi-drug-resistant tuberculosis (TB), advancing in the global fight against TB.
• GlaxoSmithKline entered a strategic partnership with a biotech firm to develop a new antifungal drug to combat invasive fungal infections.
• Johnson & Johnson introduced an innovative vaccine for preventing the spread of respiratory syncytial virus (RSV), aiming to reduce hospitalizations among high-risk populations.

List of Leading Companies:

• Pfizer Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bayer AG
• Novartis International AG
• Eli Lilly and Co.
• AstraZeneca
• Roche Pharmaceuticals
• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.

Report Scope: